A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

June 2, 2008

Primary Completion Date

December 3, 2009

Study Completion Date

December 3, 2009

Conditions
Atherosclerosis
Interventions
DRUG

LOSMAPIMOD 7.5 MG

GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.

DRUG

Placebo

Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.

Trial Locations (4)

OX3 9DU

GSK Investigational Site, Oxford

CB2 2GG

GSK Investigational Site, Cambridge

E1 1B3

GSK Investigational Site, London

Se1 7EH

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00633022 - A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging | Biotech Hunter | Biotech Hunter